25
Jul
2022
Blog
News & Views
Search
20
Jun
2022
Bionest
New EU Preparedness and Response Agency, HERA, Capitalizes on Lessons from the COVID-19 Pandemic 
Will the EU's new European Health Emergency Preparedness & Response Authority (HERA), successfully improve pandemic-preparedness & mitigate drug shortages?
6
Jun
2022
Bionest
NIH’s All of Us Project Achieves Key Milestone
The NIH launched the All of Us project in 2015 with the ambitious goal of building a database of fully sequenced genomes from at least 1m Americans. How has it fared so far?
23
May
2022
Bionest
New CheckPoint Inhibitor Therapeutic Approved, More on the Way
What effect will the introduction of Opdualag’s fixed-dose combination have on the future of checkpoint inhibitor development and approvals?
9
May
2022
Bionest
Moving Towards a Unified EU Health Policy – Beating Cancer Report Approved
The European Parliament's Beating Cancer (BECA) report addresses cancer prevention, diagnosis & treatment, with an emphasis on ensuring equitable access to quality care and support for cancer survivors and their families.
25
Apr
2022
Bionest
Biosimilars on the Rise, Spurring Company Integration and Consolidation
From one to 34: Biosimilars are on the rise. How will it affect the pharmaceutical market for companies and consumers?
11
Apr
2022
Bionest
Use of Decentralized Trials Growing, But Barriers to Adoption Remain
Despite their benefits, decentralized clinical trials still face many barriers to widespread adoption. What will it take to overcome them?
28
Mar
2022
Bionest
ASH 2021 Update: Part 2
A look at new hematology therapy developments for hemophilia, beta thalassemia and sickle cell disease presented at ASH 2021.
14
Mar
2022
Bionest
ASH 2021 Update: Part One
Are anti-CD38 antibodies & CAR-T treatments living up to their promise for multiple myeloma patients? We examine clinical trial results shared at ASH2021
28
Feb
2022